Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Actelion Ltd. (OTC: ALIOF).

Full DD Report for ALIOF

You must become a subscriber to view this report.

Recent News from (OTC: ALIOF)

Arena Pharm's long-acting ralinepag shows encouraging action in early-stage studies; shares up 2%
Arena Pharmaceuticals ( ARNA +1.9% ) is up on average volume on the heels of its announcement of data from two Phase 1 clinical trials evaluating the pharmacokinetics of its extended-release formulation of ralinepag, a prostacyclin receptor agonist in development for the treatment of pul...
Source: SeekingAlpha
Date: August, 28 2018 15:23
Liquidia Technologies Readies $50 Million IPO
Quick Take Liquidia Technologies ( LQDA ) intends to raise $50 million from the sale of its common stock in a U.S. IPO, according to an amended S-1/A registration statement . The company is advancing a pipeline of already-approved treatments using its proprietary dry inhaled technology....
Source: SeekingAlpha
Date: July, 19 2018 14:29
Liquidia Technologies Starts IPO Process
Quick Take Liquidia Technologies ( LQDA ) intends to sell shares of its common stock for gross proceeds of $57.5 from a U.S. IPO, according to an S-1 registration statement . The firm is a biopharmaceutical company that improves the development of new therapies by engineering drug parti...
Source: SeekingAlpha
Date: July, 03 2018 12:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALIOF.

About Actelion Ltd. (OTC: ALIOF)

Logo for Actelion Ltd. (OTC: ALIOF)

Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, that focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.




Current Management

  • Jean Paul Clozel / CEO
    • JeanPaul Clozel d.o.b. April is a cardiologist educated in France, with further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco. After eleven years as a clinician, he decided to move to applied research. During his years at F. HoffmannLa Roche Ltd, he was responsible for the selection of the first Tchannel blocker. He also participated in the characterization of renin inhibitors as well as several endothelin receptor antagonists such as bosentan and clazosentan. Overall, the group he was heading discovered seven compounds that entered clinical trials. During his yearcareer in cardiology, he has published widely in peerreviewed medical and scientific journals. At the same time, his passion has remained unchanged: being involved as closely as possible in bringing innovative medicine to his patients. He has developed various, novel experimental models allowing the differentiation of these drugs, work honored with the HoffmannLa Roche Research Prize. In he was nominated professor at the Coll ge de France in Paris, France Chair of Technical Innovation . At the end of , JeanPaul founded Actelion, together with his wife, Martine, and work colleagues and friends Walter Fischli and Thomas Widmann. First mainly focusing on Research and Development, he became CEO of the company to bring Actelion to the public in April .
  • Konrad A. Wirz / CFO
  • Andrew Oakley / CFO
  • Andre C. Muller / CFO
    • Andre C. Muller is a French citizen and holds an MBA from the Business School EM Lyon. Andre joins Actelion from Pierre Fabre SA, an international pharmaceutical and cosmetic group where he held various position from until , most recently as Chief Financial Officer. Andre joined Actelion in September , as Executive VicePresident, Chief Financial Officer and a member of the Actelion Executive Committee.
  • Otto Schwarz / EVP, COO
    • Otto Schwarz is an Austrian citizen with a PhD in pharmaceutical chemistry from Vienna University. Prior to joining Actelion, he was Executive VicePresident Commercial Operations at Nycomed former Altana Pharma AG where he oversaw commercial operations in more than countries. Previously, Otto worked for almost years at Eli Lilly and ScheringPlough providing him with the opportunity to either lead or participate in major drug launches and major strategic alliances with third parties. Otto joined Actelion in and is currently Executive VicePresident, Chief Operating Officer and a member of the Actelion Executive Committee.
  • Tom Monroe / VP, Fin.
  • Mareike Borchert / IR Manager

Current Share Structure

  • Market Cap: $36,235,217,250 - 03/15/2018
  • Issue and Outstanding: 130,108,500 - 03/31/2011


Daily Technical Chart for (OTC: ALIOF)

Daily Technical Chart for (OTC: ALIOF)

Stay tuned for daily updates and more on (OTC: ALIOF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ALIOF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALIOF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALIOF and does not buy, sell, or trade any shares of ALIOF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: